NEW YORK – Advanced BioScience Laboratories said Monday it signed a seven-year contract worth up to $12 million with the US National Institutes of Health's National Institute of Allergy and Infectious Diseases for the delivery of diagnostics development services.
ABL said that under the contract with the NIAID Division of Microbiology and Infectious Diseases, the Rockville, Maryland-based firm will support the agency through the development, documentation, and production of custom recombinant proteins and monoclonal antibodies for use in in vitro diagnostic assays. The deal struck under the NIAID's Diagnostics Preclinical Services program is ABL's fourth indefinite delivery and indefinite quantity contract inked with the NIH since 2021.
Timothy Fouts, vice president of innovation and translation at ABL, said in a statement the contract "confirms ABL's role as a trusted partner of the US government and the biopharmaceutical industry. It showcases ABL's capabilities in product development, manufacturing, and testing and it reinforces our commitment to providing comprehensive solutions in the field of diagnostics," he said.
ABL, part of the Institut Mérieux, is a contract research and manufacturing organization with a focus on therapeutics, vaccines, and other biological products.